Product Code: IRTNTR70326
Technavio has been monitoring the retinal drugs market and is forecast to grow by $7275.79 mn during 2022-2027, accelerating at a CAGR of 6.27% during the forecast period. Our report on the retinal drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in prevalence of retinal diseases, emergence of advanced diagnostic tools, and patient assistance programs.
Technavio's retinal drugs market is segmented as below:
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
By Indication
- Macular degeneration
- Diabetic eye disease
- Others
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the development of innovative therapies as one of the prime reasons driving the retinal drugs market growth during the next few years. Also, rise in demand for sustained-release ocular formulations and advances in diagnostic techniques will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the retinal drugs market covers the following areas:
- Retinal drugs market sizing
- Retinal drugs market forecast
- Retinal drugs market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading retinal drugs market vendors that include Bayer AG, AbbVie Inc., Alcon Inc., Alimera Sciences Inc., Bausch Health Co Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Kubota Corp., MeiraGTx Holdings Plc, Novartis AG, Ocular Therapeutix Inc., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc., REGENXBIO Inc, Sanofi SA, Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Visufarma, and Johnson and Johnson Services Inc. Also, the retinal drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary - Chart on Market Overview
- Exhibit 02: Executive Summary - Data Table on Market Overview
- Exhibit 03: Executive Summary - Chart on Global Market Characteristics
- Exhibit 04: Executive Summary - Chart on Market by Geography
- Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
- Exhibit 06: Executive Summary - Chart on Market Segmentation by Indication
- Exhibit 07: Executive Summary - Chart on Incremental Growth
- Exhibit 08: Executive Summary - Data Table on Incremental Growth
- Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global retinal drugs market 2017 - 2021
- Exhibit 18: Historic Market Size - Data Table on Global retinal drugs market 2017 - 2021 ($ million)
- 4.2 Ditribution channel Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size - Ditribution channel Segment 2017 - 2021 ($ million)
- 4.3 Indication Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size - Indication Segment 2017 - 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Distribution Channel
- 6.1 Market segments
- Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
- 6.2 Comparison by Distribution Channel
- Exhibit 32: Chart on Comparison by Distribution Channel
- Exhibit 33: Data Table on Comparison by Distribution Channel
- 6.3 Hospital pharmacy - Market size and forecast 2022-2027
- Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
- 6.4 Retail pharmacy - Market size and forecast 2022-2027
- Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
- 6.5 Online pharmacy - Market size and forecast 2022-2027
- Exhibit 42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)
- 6.6 Market opportunity by Distribution Channel
- Exhibit 46: Market opportunity by Distribution Channel ($ million)
7 Market Segmentation by Indication
- 7.1 Market segments
- Exhibit 47: Chart on Indication - Market share 2022-2027 (%)
- Exhibit 48: Data Table on Indication - Market share 2022-2027 (%)
- 7.2 Comparison by Indication
- Exhibit 49: Chart on Comparison by Indication
- Exhibit 50: Data Table on Comparison by Indication
- 7.3 Macular degeneration - Market size and forecast 2022-2027
- Exhibit 51: Chart on Macular degeneration - Market size and forecast 2022-2027 ($ million)
- Exhibit 52: Data Table on Macular degeneration - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Chart on Macular degeneration - Year-over-year growth 2022-2027 (%)
- Exhibit 54: Data Table on Macular degeneration - Year-over-year growth 2022-2027 (%)
- 7.4 Diabetic eye disease - Market size and forecast 2022-2027
- Exhibit 55: Chart on Diabetic eye disease - Market size and forecast 2022-2027 ($ million)
- Exhibit 56: Data Table on Diabetic eye disease - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Chart on Diabetic eye disease - Year-over-year growth 2022-2027 (%)
- Exhibit 58: Data Table on Diabetic eye disease - Year-over-year growth 2022-2027 (%)
- 7.5 Others - Market size and forecast 2022-2027
- Exhibit 59: Chart on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 60: Data Table on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 62: Data Table on Others - Year-over-year growth 2022-2027 (%)
- 7.6 Market opportunity by Indication
- Exhibit 63: Market opportunity by Indication ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 65: Chart on Market share by geography 2022-2027 (%)
- Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 67: Chart on Geographic comparison
- Exhibit 68: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Europe - Market size and forecast 2022-2027
- Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.5 Asia - Market size and forecast 2022-2027
- Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 China - Market size and forecast 2022-2027
- Exhibit 89: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 90: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 91: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.9 Germany - Market size and forecast 2022-2027
- Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.10 Spain - Market size and forecast 2022-2027
- Exhibit 97: Chart on Spain - Market size and forecast 2022-2027 ($ million)
- Exhibit 98: Data Table on Spain - Market size and forecast 2022-2027 ($ million)
- Exhibit 99: Chart on Spain - Year-over-year growth 2022-2027 (%)
- Exhibit 100: Data Table on Spain - Year-over-year growth 2022-2027 (%)
- 9.11 Canada - Market size and forecast 2022-2027
- Exhibit 101: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 102: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 103: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 104: Data Table on Canada - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 105: Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 106: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 108: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 109: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 110: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 111: Matrix on vendor position and classification
- 12.3 AbbVie Inc.
- Exhibit 112: AbbVie Inc. - Overview
- Exhibit 113: AbbVie Inc. - Product / Service
- Exhibit 114: AbbVie Inc. - Key news
- Exhibit 115: AbbVie Inc. - Key offerings
- 12.4 Alcon Inc.
- Exhibit 116: Alcon Inc. - Overview
- Exhibit 117: Alcon Inc. - Business segments
- Exhibit 118: Alcon Inc. - Key offerings
- Exhibit 119: Alcon Inc. - Segment focus
- 12.5 Alimera Sciences Inc.
- Exhibit 120: Alimera Sciences Inc. - Overview
- Exhibit 121: Alimera Sciences Inc. - Product / Service
- Exhibit 122: Alimera Sciences Inc. - Key offerings
- 12.6 Bausch Health Co Inc.
- Exhibit 123: Bausch Health Co Inc. - Overview
- Exhibit 124: Bausch Health Co Inc. - Business segments
- Exhibit 125: Bausch Health Co Inc. - Key news
- Exhibit 126: Bausch Health Co Inc. - Key offerings
- Exhibit 127: Bausch Health Co Inc. - Segment focus
- 12.7 Bayer AG
- Exhibit 128: Bayer AG - Overview
- Exhibit 129: Bayer AG - Business segments
- Exhibit 130: Bayer AG - Key news
- Exhibit 131: Bayer AG - Key offerings
- Exhibit 132: Bayer AG - Segment focus
- 12.8 Bristol Myers Squibb Co.
- Exhibit 133: Bristol Myers Squibb Co. - Overview
- Exhibit 134: Bristol Myers Squibb Co. - Product / Service
- Exhibit 135: Bristol Myers Squibb Co. - Key news
- Exhibit 136: Bristol Myers Squibb Co. - Key offerings
- 12.9 F. Hoffmann La Roche Ltd.
- Exhibit 137: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 138: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 139: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 140: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 141: F. Hoffmann La Roche Ltd. - Segment focus
- 12.10 Johnson and Johnson Services Inc.
- Exhibit 142: Johnson and Johnson Services Inc. - Overview
- Exhibit 143: Johnson and Johnson Services Inc. - Business segments
- Exhibit 144: Johnson and Johnson Services Inc. - Key news
- Exhibit 145: Johnson and Johnson Services Inc. - Key offerings
- Exhibit 146: Johnson and Johnson Services Inc. - Segment focus
- 12.11 MeiraGTx Holdings Plc
- Exhibit 147: MeiraGTx Holdings Plc - Overview
- Exhibit 148: MeiraGTx Holdings Plc - Product / Service
- Exhibit 149: MeiraGTx Holdings Plc - Key offerings
- 12.12 Novartis AG
- Exhibit 150: Novartis AG - Overview
- Exhibit 151: Novartis AG - Business segments
- Exhibit 152: Novartis AG - Key offerings
- Exhibit 153: Novartis AG - Segment focus
- 12.13 Ocular Therapeutix Inc.
- Exhibit 154: Ocular Therapeutix Inc. - Overview
- Exhibit 155: Ocular Therapeutix Inc. - Product / Service
- Exhibit 156: Ocular Therapeutix Inc. - Key offerings
- 12.14 Oxurion NV
- Exhibit 157: Oxurion NV - Overview
- Exhibit 158: Oxurion NV - Product / Service
- Exhibit 159: Oxurion NV - Key offerings
- 12.15 Pfizer Inc.
- Exhibit 160: Pfizer Inc. - Overview
- Exhibit 161: Pfizer Inc. - Product / Service
- Exhibit 162: Pfizer Inc. - Key news
- Exhibit 163: Pfizer Inc. - Key offerings
- 12.16 Regeneron Pharmaceuticals Inc.
- Exhibit 164: Regeneron Pharmaceuticals Inc. - Overview
- Exhibit 165: Regeneron Pharmaceuticals Inc. - Product / Service
- Exhibit 166: Regeneron Pharmaceuticals Inc. - Key offerings
- 12.17 Sanofi SA
- Exhibit 167: Sanofi SA - Overview
- Exhibit 168: Sanofi SA - Business segments
- Exhibit 169: Sanofi SA - Key news
- Exhibit 170: Sanofi SA - Key offerings
- Exhibit 171: Sanofi SA - Segment focus
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 172: Inclusions checklist
- Exhibit 173: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 174: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 175: Research methodology
- Exhibit 176: Validation techniques employed for market sizing
- Exhibit 177: Information sources
- 13.5 List of abbreviations
- Exhibit 178: List of abbreviations